Answers are grounded in this paper and cite their sources.
Synthesis of benzylamino benzoic acid derivatives showed antibacterial effects and promising anticancer activity, indicating potential therapeutic applications.
A series of 4-(benzylamino)-benzoic acid derivatives ArCH2NH-4-C6H4CO2H (1-19) (Ar = C6H5 (1); 4-Cl-C6H4 (2); 4-NMe-C6H4 (3); 4-Br-C6H4 (4); 3-NO2-C6H4 (5); 4-NO2-C6H4 (6); 2-OMe-C6H4 (7); 3-OMe-C6H4 (8); 4-OMe-C6H4 (9); 2,3-OMe-C6H3 (10); 3,4-OMe-C6H3 (11); 2-OH, 3-OMe-C6H3 (12); 3-OMe, 4-OH-C6H3 (13); 3,5-OMe, 4-OH-C6H4 (14); 2-OH-5-Br-C6H3 (15), 3-OH-C6H4 (16); 4-SMe-C6H4 (17); 2,3-OH-C6H3 (18); 3-CF3-C6H4 (19)) were synthesized via reductive amination of p-aminobenzoic acid with substituted benzaldehydes and sodium borohydride. The structures were confirmed by MS, FT-IR, NMR, and E.A., with single-crystal X-ray diffraction elucidating key intermolecular interactions in compounds 2, 4, 7-9 and 11. Hirshfeld surface analysis and 2D fingerprint plots highlighted noncovalent interactions contributing to crystal packing. DFT calculations (PBE0/def2-TZVP/CPCM) provided optimized geometries, HOMO-LUMO gaps, and electrostatic surface potentials. TD-DFT simulations supported experimental UV-vis spectra. Several derivatives (2, 3, 5, 7, 8, 10, 11, 13-16) showed moderate antibacterial activity (MIC = 64-128 μg/mL) against different strains of bacteria, while compound 18 exhibited promising anticancer activity with IC50 values of 90.69 μM against Non-Small Cell Lung Cancer cell line (A549) and 32.22 μM against Small Cell Lung Cancer cell line (H69).
No takes yet. Share an insight, caveat, or question.
Hijazi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: